Merck & Co. (MRK) : Ingalls Snyder scooped up 6,718 additional shares in Merck & Co. during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 11, 2016. The investment management firm now holds a total of 335,373 shares of Merck & Co. which is valued at $21,245,880.Merck & Co. makes up approximately 1.20% of Ingalls Snyder’s portfolio.
Other Hedge Funds, Including , Azimuth Capital Management reduced its stake in MRK by selling 393 shares or 0.16% in the most recent quarter. The Hedge Fund company now holds 243,309 shares of MRK which is valued at $15,413,625. Merck & Co. makes up approx 1.34% of Azimuth Capital Management’s portfolio. Tradelink Capital added MRK to its portfolio by purchasing 3,520 company shares during the most recent quarter which is valued at $202,928. Merck & Co. makes up approx 0.94% of Tradelink Capital’s portfolio.Sit Investment Associates Inc reduced its stake in MRK by selling 327,775 shares or 53.22% in the most recent quarter. The Hedge Fund company now holds 288,150 shares of MRK which is valued at $16,902,879. Merck & Co. makes up approx 0.44% of Sit Investment Associates Inc’s portfolio.Vnbtrust National Association boosted its stake in MRK in the latest quarter, The investment management firm added 75 additional shares and now holds a total of 11,652 shares of Merck & Co. which is valued at $682,807. Merck & Co. makes up approx 0.40% of Vnbtrust National Association’s portfolio.Country Club Trust Company N.a. boosted its stake in MRK in the latest quarter, The investment management firm added 5,202 additional shares and now holds a total of 134,265 shares of Merck & Co. which is valued at $7,897,467. Merck & Co. makes up approx 1.11% of Country Club Trust Company N.a.’s portfolio.
Merck & Co. opened for trading at $63.71 and hit $63.88 on the upside on Tuesday, eventually ending the session at $63.58, with a gain of 0.05% or 0.03 points. The heightened volatility saw the trading volume jump to 57,98,353 shares. Company has a market cap of $175,812 M.
On the company’s financial health, Merck & Co. reported $0.93 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Jul 29, 2016. Analyst had a consensus of $0.91. The company had revenue of $9844.00 million for the quarter, compared to analysts expectations of $9782.80 million. The company’s revenue was up .6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.86 EPS.
Investors should note that on Jul 26, 2016, Merck & Co. announced a cash dividend of $0.4600. The company’s management has announced Sep 13, 2016 as the ex-dividend date and fixed the record date on Sep 15, 2016. The payable date has been fixed on Oct 7, 2016.
Many Wall Street Analysts have commented on Merck & Co.. Credit Suisse Upgraded Merck & Co. on Aug 8, 2016 to ” Outperform”, Price Target of the shares are set at $73.Company shares were Reiterated by Deutsche Bank on Aug 8, 2016 to “Hold”, Firm has raised the Price Target to $ 59 from a previous price target of $58 .
Merck & Co. Inc. is a global health care company. The Company offers health solutions through its prescription medicines vaccines biologic therapies and animal health products which it markets directly and through its joint ventures. The Companys Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents generally sold by prescription for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers hospitals government agencies and managed health care providers. The Animal Health segment discovers develops manufactures and markets animal health products including vaccines. The Companys animal health products are sold to veterinarians distributors and animal producers.